Early trial probes new drug cocktail for Tough-to-Treat lymphomas
NCT ID NCT04447716
Summary
This early-stage study is testing the safety and best dose of a three-drug combination for patients with follicular or marginal zone lymphoma that has come back or not responded to prior treatment. The drugs—venetoclax, lenalidomide, and rituximab hyaluronidase—work together to help the immune system fight cancer and block proteins that help cancer cells survive. The main goal is to see if this combination is safe for patients and to find the right dose for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY FOLLICULAR LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.